These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31335285)

  • 1. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.
    Panda A; Obmann VC; Lo WC; Margevicius S; Jiang Y; Schluchter M; Patel IJ; Nakamoto D; Badve C; Griswold MA; Jaeger I; Ponsky LE; Gulani V
    Radiology; 2019 Sep; 292(3):685-694. PubMed ID: 31335285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
    Panda A; OʼConnor G; Lo WC; Jiang Y; Margevicius S; Schluchter M; Ponsky LE; Gulani V
    Invest Radiol; 2019 Aug; 54(8):485-493. PubMed ID: 30985480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.
    Yu AC; Badve C; Ponsky LE; Pahwa S; Dastmalchian S; Rogers M; Jiang Y; Margevicius S; Schluchter M; Tabayoyong W; Abouassaly R; McGivney D; Griswold MA; Gulani V
    Radiology; 2017 Jun; 283(3):729-738. PubMed ID: 28187264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the Utility of PI-RADS 2.1, ADC Values, and Combined Use of Both, for the Diagnosis of Transition Zone Prostate Cancers.
    Liu X; Xiong Q; Zeng W; Yang R; Wen Y; Li X
    J Comput Assist Tomogr; 2024 Mar-Apr 01; 48(2):206-211. PubMed ID: 38149651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 8. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS Version 2: A Pictorial Update.
    Purysko AS; Rosenkrantz AB; Barentsz JO; Weinreb JC; Macura KJ
    Radiographics; 2016; 36(5):1354-72. PubMed ID: 27471952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens.
    Hoeks CM; Vos EK; Bomers JG; Barentsz JO; Hulsbergen-van de Kaa CA; Scheenen TW
    Invest Radiol; 2013 Oct; 48(10):693-701. PubMed ID: 23614975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of prostatitis and prostate cancer using the Prostate Imaging-Reporting and Data System (PI-RADS).
    Meier-Schroers M; Kukuk G; Wolter K; Decker G; Fischer S; Marx C; Traeber F; Sprinkart AM; Block W; Schild HH; Willinek W
    Eur J Radiol; 2016 Jul; 85(7):1304-11. PubMed ID: 27235878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
    Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    Thai JN; Narayanan HA; George AK; Siddiqui MM; Shah P; Mertan FV; Merino MJ; Pinto PA; Choyke PL; Wood BJ; Turkbey B
    Radiology; 2018 Aug; 288(2):485-491. PubMed ID: 29786491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
    Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
    Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of T
    Klingebiel M; Schimmöller L; Weiland E; Franiel T; Jannusch K; Kirchner J; Hilbert T; Strecker R; Arsov C; Wittsack HJ; Albers P; Antoch G; Ullrich T
    J Magn Reson Imaging; 2022 Aug; 56(2):413-422. PubMed ID: 35038203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
    Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
    Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
    Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
    In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
    Yim JH; Kim CK; Kim JH
    J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.